Chemistry:Zonampanel
From HandWiki
Short description: Chemical compound
 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C13H9N5O6 |
| Molar mass | 331.244 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Zonampanel (INN, code name YM872) is a quinoxalinedione derivative drug and competitive antagonist of the AMPA receptor which was being investigated by Yamanouchi/Astellas Pharma as a neuroprotective drug for the treatment of ischemic stroke but never completed clinical trials.[1][2][3][4] In clinical trials, zonampanel produced severe side effects including hallucinations, agitation, and catatonia in patients, resulting in early termination of the trials.[5]
References
- ↑ The Handbook of Neuroprotection. Springer Science & Business Media. 14 February 2011. pp. 154–. ISBN 978-1-61779-049-2. https://books.google.com/books?id=PGZ3Qqvjmo0C&pg=PA154.
- ↑ Current Trends in Pharmacology. I. K. International Pvt Ltd. 1 January 2007. pp. 321–. ISBN 978-81-88237-77-7. https://books.google.com/books?id=uB2vWIQBbxoC&pg=PA321.
- ↑ Multiple Sclerosis As A Neuronal Disease. Academic Press. 27 May 2005. pp. 245–. ISBN 978-0-08-048941-4. https://books.google.com/books?id=Eeqy733NZSEC&pg=PA245.
- ↑ Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS. Springer Science & Business Media. 31 January 2007. pp. 37–. ISBN 978-0-306-48644-9. https://books.google.com/books?id=wcjiZ58mypIC&pg=PA37.
- ↑ Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. Springer Science & Business Media. 2 September 2010. pp. 73–. ISBN 978-1-4419-6652-0. https://books.google.com/books?id=q_G5aon0WbAC&pg=PA73.
 |  |
